Abstract
The aim of this study was to evaluate the effect of sildenafil on ocular hemodynamics in a group of men with erectile dysfunction in 3 months regular use. A total of 15 patients with erectile dysfunction were included in this prospective study. All patients received 50 mg doses of sildenafil (Viagra, Pfizer) two times per week regularly for 3 months. The following examinations were performed on both eyes before and after sildenafil treatment: best-corrected visual acuity (BCVA), intraocular pressure (IOP), color vision, anterior segment, and fundus examination. Using color Doppler imaging, we measured hemodynamic variables in the ophthalmic artery (OA), central retinal artery (CRA), and short posterior ciliary artery (SPCA). No significant changes in BCVA, color vision and IOP were found after sildenafil treatment. The anterior segment and fundus examinations showed no abnormalities. All Doppler parameters of OA, CRA, and SPCA remained nonsignificant for both eyes after sildenafil treatment. Oral sildenafil in 3 months regular use seems to have no effect on ocular hemodynamics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 8 print issues and online access
$259.00 per year
only $32.38 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Boolell M, Gepi-Attee S, Gingell JC, Allen MJ . Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257–261.
Burnett AL . Role of nitric oxide in the physiology of erection. Biol Reprod 1995; 52: 485–489.
Terrett NK, Bell AS, Brown D, Ellis P . Sildenafil (Viagra), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. Bioorg Med Chem Lett 1996; 6: 1819–1824.
Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA . Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397–1404.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.
Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM . Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164–2171.
Moreland RB, Goldstein I, Traish A . Sildenafil, a novel inhibitor of phosphodiesterase type 5 human corpus cavernosum smooth muscle cells. Life Sci 1998; 62: 309–318.
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM et al. Sildenafil: an orally type 5 cyclic GMP-spesific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47–52.
Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD . Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958–963.
Waldman SA, Murad F . Cyclic GMP synthesis and function. Pharmacol Rev 1987; 39: 163–196.
Rendell MS, Rajfer J, Wicker PA, Smith MD . Sildenafil for treatment of erectile dysfunction in men with diabetes. JAMA 1999; 281: 421–426.
Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M . Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998; 15: 821–825.
Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH . Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69–74.
Center for Drug Evaluation and Research. Viagra Tablets (Sildenafil Citrate): Review and Evaluation of Pharmocology and Toxicology Data for NDA-20-895. Division of Cardio-renal Drug Products, Center for Drug Evaluation and Research, Food and Drug Administration: Washington DC 1998, pp 19–21.
Center for Drug Evaluation and Research. Animal pharmacology: mechanism of action, section 4.2. In: Viagra (sildenafil): joint clinical review for NDA-20-895. Center for Drug Evaluation and Research. Food and Drug Administration, Washington, DC, 1998, 4p.
Vobig MA, Klotz T, Staak M, Bartz-Schmidt KU, Engelmann U, Walter P . Retinal side effects of sildenafil. Lancet 1999; 353: 375.
Zrenner E, Koppiker NP, Smith MD, Constable I, Littlewood R, Stuckey B . The effects of long-term sildenafil treatment on ocular safety in patients with erectile dysfunction. Invest Ophthalmol Vis Sci 2000; 41: S592.
Grunwald JE, Siu KK, Jacob SS, Dupont J . Effect of sildenafil citrate (Viagra) on the ocular circulation. Am J Ophthalmol 2001; 131: 751–755.
Sponsel WE, Paris G, Sandoval SS, Sanford DK, Harrison JM, Elliott WR et al. Sildenafil and ocular perfusion. N Eng J Med 2000; 342: 1680.
Harris A, Williamson TH, Martin B, Shoemaker JA, Sergott RC, Spaeth GL et al. Test/retest reproducibility of color Doppler imaging assessment of blood flow velocity in orbital vessels. J Glaucoma 1995; 4: 281–286.
Dundar SO, Dundar M, Kocak I, Dayanir Y, Ozkan SB . Effect of sildenafil on ocular hemodynamics. Eye 2001; 15: 507–510.
Kurtulan E, Gulcu A, Secil M, Celebi I, Aslan G, Esen AA . Effects of sildenafil on ocular perfusion demonstrated by color Doppler ultrasonography. Int J Impot Res 2004; 16: 244–248.
Vatansever HS, Kayikcioglu O, Gumus B . Histopathologic effect of chronic use of sildenafil citrate on the choroid and retina in male rats. Indian J Med Res 2003; 117: 211–215.
Moncada S, Radomski MW, Palmer RMJ . Endothelium derived relaxing factor: identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988; 37: 2495–2501.
Gardiner SM, Compton AM, Bennett T, Palmer RM, Moncada S . Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15: 486–492.
Kelly PA, Buckley CH, Ritchie IM, O’Brien C . Possible role for nitric oxide releasing nerves in the regulation of ocular blood flow in the rat. Br J Ophthalmol 1998; 82: 1199–1202.
Roufail E, Stringer M, Rees S . Nitric oxide synthase immunoreactivity and NADH diaphorase staining are colocalised in neurones closely associated with the vasculature in rat and human retina. Brain Res 1995; 684: 36–46.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dündar, S., Dayanir, Y., Topaloğlu, A. et al. Effect of sildenafil on ocular hemodynamics in 3 months regular use. Int J Impot Res 18, 282–286 (2006). https://doi.org/10.1038/sj.ijir.3901416
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.ijir.3901416
Keywords
This article is cited by
-
Chronic sildenafil citrate use decreases retinal vascular endothelial growth factor expression in diabetic rats: a pilot study
International Journal of Retina and Vitreous (2023)
-
Monitor recipients of phosphodiesterase type 5 inhibitors for glaucoma, pending more clinical evidence of risk
Drugs & Therapy Perspectives (2020)
-
Precautions and Monitoring of Patients Taking Phosphodiesterase Type 5 Inhibitors Who are at Risk of Increased Intraocular Pressure
Drugs & Aging (2019)
-
Ocular perfusion pressure and color Doppler imaging of the external ophthalmic artery of rabbits treated with sildenafil citrate
BMC Veterinary Research (2016)
-
Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: Is there a link?
Current Urology Reports (2007)